Payment overview · 2025
General Payments
$161.18
10 reported records · 7 companies
Healthcare provider profile · identity verified
Sunil Chandra, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORTHPORT, AL · NPI 1417060666
Verified facts
What the public records show
CMS Open Payments records show Sunil Chandra, M.D. received $161.18 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.54 | 21.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.17 | 21.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.16 | 21.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.27 | 9.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.78 | 9.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.74 | 9.2% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $13.52 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.66 | 9 |
| Entertainment | $13.52 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 565 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 233 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 526 | 118 |
| Potassium Chloride | Potassium Chloride | 509 | 216 |
| Levothyroxine Sodium | Levothyroxine Sodium | 498 | 166 |
| Omeprazole | Omeprazole | 379 | 175 |
| Gabapentin | Gabapentin | 368 | 117 |
| Losartan Potassium | Losartan Potassium | 361 | 150 |
| Alprazolam | Alprazolam | 359 | 48 |
| Furosemide | Furosemide | 334 | 150 |
| Pravastatin Sodium | Pravastatin Sodium | 312 | 117 |
| Tramadol Hcl | Tramadol Hcl | 298 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 116 |
| Metformin Hcl | Metformin Hcl | 267 | 100 |
| Carvedilol | Carvedilol | 240 | 93 |
| Eliquis | Apixaban | 220 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 188 | 85 |
| Alendronate Sodium | Alendronate Sodium | 186 | 74 |
| Lisinopril | Lisinopril | 185 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 74 |
| Trazodone Hcl | Trazodone Hcl | 176 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 54 |
| Clonidine Hcl | Clonidine Hcl | 164 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 76 |
| Sertraline Hcl | Sertraline Hcl | 158 | 52 |
| Clonazepam | Clonazepam | 154 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 149 | 60 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 64 |
| Montelukast Sodium | Montelukast Sodium | 149 | 68 |
| Temazepam | Temazepam | 139 | 24 |
| Meloxicam | Meloxicam | 135 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 73 |
| Allopurinol | Allopurinol | 129 | 55 |
| Glimepiride | Glimepiride | 128 | 50 |
| Famotidine | Famotidine | 125 | 53 |
| Mirtazapine | Mirtazapine | 104 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 61 |
| Simvastatin | Simvastatin | 100 | 41 |
| Jardiance | Empagliflozin | 99 | 43 |
| Mounjaro | Tirzepatide | 99 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 49 |
| Celecoxib | Celecoxib | 96 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 32 |
| Ezetimibe | Ezetimibe | 91 | 39 |
| Januvia | Sitagliptin Phosphate | 90 | 34 |
| Ozempic | Semaglutide | 90 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 73 |
| Buspirone Hcl | Buspirone Hcl | 87 | 25 |
| Pregabalin | Pregabalin | 86 | 18 |
| Torsemide | Torsemide | 86 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 32 |
| Glipizide | Glipizide | 79 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 29 |
| Prednisone | Prednisone | 74 | 50 |
| Spironolactone | Spironolactone | 73 | 32 |
| Lorazepam | Lorazepam | 72 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 36 |
| Methocarbamol | Methocarbamol | 69 | 45 |
| Farxiga | Dapagliflozin Propanediol | 68 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | 24 |
| Azithromycin | Azithromycin | 62 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 21 |
| Nifedipine Er | Nifedipine | 59 | 25 |
| Valsartan | Valsartan | 57 | 26 |
| Atenolol | Atenolol | 55 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 45 |
| Candesartan Cilexetil | Candesartan Cilexetil | 53 | 12 |
| Donepezil Hcl | Donepezil Hcl | 53 | 21 |
| Myrbetriq | Mirabegron | 53 | 16 |
| Fluconazole | Fluconazole | 50 | 31 |
| Cefuroxime | Cefuroxime Axetil | 47 | 42 |
| Enalapril Maleate | Enalapril Maleate | 47 | 21 |
| Memantine Hcl | Memantine Hcl | 47 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 22 |
| Nabumetone | Nabumetone | 46 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 17 |
| Metformin Hcl Er | Metformin Hcl | 43 | 20 |
| Meclizine Hcl | Meclizine Hcl | 42 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 24 |
| Entresto | Sacubitril/Valsartan | 39 | 14 |
| Glipizide Er | Glipizide | 39 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 15 |
| Benazepril Hcl | Benazepril Hcl | 38 | 12 |
| Fenofibrate | Fenofibrate | 38 | 13 |
| Levetiracetam | Levetiracetam | 38 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 17 |
| Bumetanide | Bumetanide | 35 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 12 |
| Promethazine Hcl | Promethazine Hcl | 35 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 21 |
| Lovastatin | Lovastatin | 34 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 33 | 12 |
| Linzess | Linaclotide | 33 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 14 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 14 |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 27 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 26 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Colchicine | Colchicine | 25 | 13 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | 11 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | 15 |
| Nystatin | Nystatin | 20 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 11 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Multaq | Dronedarone Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Klor-Con 10 | Potassium Chloride | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $161.18 · 10 records | Amgen Inc. | KRYSTEXXA, Korlym, LOKELMA, NFC-700, OCT OPHTHALMOSCOPE, OTEZLA, Ozempic, PANORAMIC OPHTHALMOSCOPE, QULIPTA, REPATHA, REXULTI, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error